BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
16 déc. 2024 08h00 HE
|
BiomX
NESS ZIONA, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
14 nov. 2024 06h30 HE
|
BiomX
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF)...
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
12 nov. 2024 12h20 HE
|
BiomX
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
BiomX Announces a Mandatory Unit Separation
15 oct. 2024 07h00 HE
|
BiomX
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
18 sept. 2024 08h00 HE
|
BiomX
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 08h00 HE
|
BiomX
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024
03 sept. 2024 08h00 HE
|
BiomX
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
16 août 2024 10h55 HE
|
BiomX
In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units...
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
15 août 2024 06h30 HE
|
BiomX
BiomX anticipates reporting important results in 2025 for two clinical assets from the Company’s leading phage therapy pipeline Recent stockholder vote approves conversion of Series X Non-Voting...
BiomX Inc. Announces 1-for-10 Reverse Stock Split
15 août 2024 06h30 HE
|
BiomX
GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...